Allogene Therapeutics's total assets for Q1 2025 were $507.98M, a decrease of -7.42% from the previous quarter. ALLO total liabilities were $122.59M for the fiscal quarter, a -3.12% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.